From the 1/2yr report.... "Large pharmaceutical companies are interested in the SSAO enzyme for its role in various inflammatory diseases such as non-alcoholic steatohepatitis (NASH) and chronic obstructive pulmonary disease (COPD). Term sheets have been received and the Company is currently at the contract negotiation stage."
....Contract negotiation stage..... wont be far off a further announcement.
Ann: Half Yearly Report and Accounts, page-6
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
